CHO Plus, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Cell Lines for High Level Production of Protein-Based Pharmaceuticals (US 10,329,594) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Sep 1 US 12,723,244 Cell Lines for High Level Production of Protein Selected for Rapid Proliferation
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,723,244 | Cell Lines for High Level Production of Protein Selected for Rapid Proliferation In force · High confidence | In force | High confidence | |
| US 10,329,594 | Cell Lines for High Level Production of Protein-Based Pharmaceuticals In force · High confidence | In force | High confidence | |
| US 12,404,502 | Hybrid Yeast Cell Lines for High Level Production of Recombinant Protein In force · High confidence | In force | High confidence | |
| US 11,649,449 | Hybrid cell lines for high level production of a target protein In force · Medium confidence | In force | Medium confidence | |
| US 12,252,713 | Cell Hybrids as Virus Packaging Cells for High Efficiency Production of Gene Therapy Vectors and Viral Vaccines In force · Low confidence | In force | Low confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned
Showing 1 to 4 of 4, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/667,926 | Viral vector packaging cells made from cell hybrids | May 17, 2024 | Pending |
| 18/634,846 | Protein Producer Cells Made by Fusing Cells Together and Selecting for High Level Expression of a Transgene | Apr 12, 2024 | Abandoned |
| 18/391,547 | High Production of Recombinant Protein by Making Cell Hybrids and Enriching for a Preferred Mitochondrial Phenotype | Dec 20, 2023 | Pending |
| 18/332,612 | Cells selected for high mitochondria and/or reactive oxygen species for use as packaging cells for gene theraphy vectors and viral vaccines | Jun 9, 2023 | Abandoned |